{"product_id":"guerbet-marketing-mix","title":"Guerbet Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Guerbet’s product portfolio, pricing framework, distribution reach, and targeted promotions combine to drive market leadership—this preview only hints at the strategic detail inside. Get the full 4Ps Marketing Mix Analysis in an editable, presentation-ready format to save hours of research and apply actionable insights for benchmarking, strategy, or coursework. Buy the complete report to see real-world data, tactical recommendations, and ready-to-use slides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMRI Contrast Media Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet’s MRI contrast media portfolio centers on Elucirem, a high-relaxivity gadolinium agent, and Dotarem, the macrocyclic safety gold standard; combined they drove MRI contrast sales to ~€220m in FY2024, reinforcing neurovascular leadership.\u003c\/p\u003e\n\u003cp\u003eBoth agents boost lesion and tumor visibility for earlier detection; by Dec 2025 Dotarem held ~28% share in EU neurovascular MRI, and formulations prioritize high-stability molecules to cut gadolinium retention risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCT and Cath Lab Contrast Agents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe CT and cath lab contrast portfolio, led by Optiray and Xenetix, supplies iodinated agents for CT and cardiovascular imaging and accounted for an estimated €230m of Guerbet’s 2024 diagnostic sales, supporting routine workflow and repeat use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterventional Imaging and Oncology Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet’s interventional imaging and oncology solutions center on Lipiodol Ultra-Fluid for transarterial chemoembolization (TACE) in liver cancer, supporting ~10,000 procedures annually and contributing to the company’s 2024 vascular-oncology sales growth of ~12% (2024 revenue impact ~$45M). The segment also offers microcatheters, guidewires, and delivery systems for sub-millimeter navigation, improving placement accuracy and reducing procedure time by ~15%. By late 2025 Guerbet expanded oncology focus to combine imaging and therapy, targeting a minimally invasive market growing at ~8% CAGR through 2028. These products enable high-precision visualization and localized drug delivery critical for complex hepatic interventions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Devices and Injection Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpguerbet medical devices and injection systems including optivantage flowsens automate contrast delivery reducing air-embolism risk enabling precise patient-tailored dosing in these platforms supported over injections across eu hospitals.\u003e\n\u003cptheir hardware logs injection parameters and patient data cutting prep time by in trials boosting throughput recurring consumables link device sales to contrast-media revenue forming a department-wide ecosystem.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDevices: OptiVantage, FlowSens—120,000+ injections 2024\u003c\/li\u003e\n\u003cli\u003eSafety: air-embolism prevention, precise dosing\u003c\/li\u003e\n\u003cli\u003eEfficiency: ~18% prep-time reduction in clinical studies\u003c\/li\u003e\n\u003cli\u003eBusiness: consumables-hardware recurring revenue ecosystem\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptheir\u003e\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and AI Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuerbet has integrated digital tools and AI—notably Icobrain and MyGuerbet—to automate image quantification and provide data-driven insights, boosting diagnostic accuracy and department management.\u003c\/p\u003e\n\u003cp\u003eThese platforms flag anomalies and streamline reporting, lowering radiologist workload; Icobrain processes thousands of scans daily with reported sensitivity gains of ~8% in stroke detection (2024 pilot data).\u003c\/p\u003e\n\u003cp\u003eThe move shifts Guerbet from chemical-only supplier to integrated diagnostic solutions provider, contributing to its 2024 digital revenue segment growth of ~12% year-on-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIcobrain: automated quantification, ~8% sensitivity gain\u003c\/li\u003e\n\u003cli\u003eMyGuerbet: workflow and reporting tools\u003c\/li\u003e\n\u003cli\u003eThousands of scans processed daily\u003c\/li\u003e\n\u003cli\u003eDigital revenue +12% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet: €505M Contrast Portfolio + Growing Digital \u0026amp; Devices Momentum\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet’s product mix centers on MRI (Elucirem, Dotarem ~€220M FY2024), CT\/cath (Optiray, Xenetix ~€230M FY2024), oncology\/interventional (Lipiodol ~10,000 TACE\/yr, ~$45M 2024), devices (OptiVantage\/FlowSens 120k+ injections 2024), and digital (Icobrain\/MyGuerbet, +12% digital rev 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey products\u003c\/th\u003e\n\u003cth\u003e2024 figs\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMRI\u003c\/td\u003e\n\u003ctd\u003eElucirem, Dotarem\u003c\/td\u003e\n\u003ctd\u003e€220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCT\/Cath\u003c\/td\u003e\n\u003ctd\u003eOptiray, Xenetix\u003c\/td\u003e\n\u003ctd\u003e€230M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eLipiodol, devices\u003c\/td\u003e\n\u003ctd\u003e10,000 TACE; €45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices\u003c\/td\u003e\n\u003ctd\u003eOptiVantage, FlowSens\u003c\/td\u003e\n\u003ctd\u003e120,000+ inj\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003eIcobrain, MyGuerbet\u003c\/td\u003e\n\u003ctd\u003e+12% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a company-specific deep dive into Guerbet’s Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Guerbet’s 4P marketing strategy into a concise, leadership-ready snapshot that simplifies positioning, pricing, product portfolio, and promotion tactics for quick decision-making and cross-functional alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Commercial Operations in Key Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet runs direct commercial operations in the US, France, Germany and China, with onsite sales and medical affairs teams covering ~60% of its 2024 revenue (€730m total in 2024; estimate: ~€438m from these markets). \u003c\/p\u003e\n\u003cp\u003eThis model lets Guerbet control customer experience, deepen ties with key opinion leaders, and shorten product uptake cycles—direct accounts in hospitals and clinics drove a 4–6% faster adoption in contrast to distributor-led markets in 2023. \u003c\/p\u003e\n\u003cp\u003eLocal offices enable rapid responses to regulation and demand shifts; for example, the China office adjusted pricing and gained a 3% market-share increase in 2024 after the NMPA reimbursement update. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet covers over 80 countries using a network of specialized distributors, enabling access to contrast media and imaging tech in smaller markets without local offices.\u003c\/p\u003e\n\u003cp\u003ePartners are chosen for pharma logistics expertise and regulatory navigation; in 2024 distributor-sourced sales accounted for roughly 28% of Guerbet’s €630m revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Manufacturing and Production Sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet operates industrial sites across Europe and the Americas, notably major plants in Aulnay-sous-Bois, France; Athlone, Ireland; and Itu, Brazil, enabling a 25–40% cut in regional lead times for contrast agents versus centralized production (company logistics data, 2024). Each site follows EU GMP and FDA-equivalent standards to ensure product safety and batch consistency. Decentralized manufacturing reduced COVID-era supply disruptions impact by an estimated 30% on delivery KPIs in 2020–24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eE-Commerce and Digital Procurement Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy end-2025, Guerbet expanded digital distribution via professional e-commerce portals enabling hospitals to manage orders and inventory; institutional sales through these portals rose 18% year-over-year to represent 32% of D2H (direct-to-hospital) volumes.\u003c\/p\u003e\n\u003cp\u003ePlatforms give procurement officers real-time product availability, pricing, and shipping status, cutting order cycle times by ~24% and reducing stockouts by 15% in 2024 pilots.\u003c\/p\u003e\n\u003cp\u003eDigital integration simplifies bulk buying of consumables like syringes and contrast bottles, lowering procurement costs ~6% per order and improving forecast accuracy.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e2025: portals handle 32% D2H volume\u003c\/li\u003e\n\u003cli\u003e18% YoY portal sales growth\u003c\/li\u003e\n\u003cli\u003e24% faster order cycles\u003c\/li\u003e\n\u003cli\u003e15% fewer stockouts\u003c\/li\u003e\n\u003cli\u003e~6% lower per-order cost\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGuerbet relies on sophisticated cold chain logistics to preserve contrast-agent integrity, using climate-controlled storage and validated temperature ranges (2–8°C for many gadolinium and iodine formulations) during transit.\u003c\/p\u003e\n\u003cp\u003eThe company partners with DHL, Kuehne+Nagel and regional couriers to ship from production sites in France and the US, using real-time IoT tracking and 24\/7 monitoring to cut spoilage; industry spoilage rates fall below 0.5% with such systems.\u003c\/p\u003e\n\u003cp\u003eEfficient logistics support rapid replenishment to emergency departments and high-volume imaging centers, meeting service-level agreements often requiring next-day or same-day delivery in 60–85% of markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold chain 2–8°C\u003c\/li\u003e\n\u003cli\u003ePartners: DHL, Kuehne+Nagel\u003c\/li\u003e\n\u003cli\u003eIoT tracking, 24\/7 monitoring\u003c\/li\u003e\n\u003cli\u003eSpoilage \u0026lt;0.5% with controls\u003c\/li\u003e\n\u003cli\u003eNext\/same-day delivery in 60–85% of markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet: €730M, 60% direct, 32% D2H by 2025, \u0026lt;0.5% spoilage, fast cold‑chain delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet uses direct ops in US\/FR\/DE\/CN (≈60% of 2024 revenue; €730m total), distributors in 80+ countries (28% of 2024 sales), three major plants (Aulnay, Athlone, Itu) cutting lead times 25–40%, digital portals handling 32% D2H by 2025 (18% YoY), cold chain 2–8°C, spoilage \u0026lt;0.5%, next\/same-day delivery in 60–85% markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e€730m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect markets\u003c\/td\u003e\n\u003ctd\u003e≈60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor share\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eD2H portals 2025\u003c\/td\u003e\n\u003ctd\u003e32%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eGuerbet 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Guerbet 4P's Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750286045561,"sku":"guerbet-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/guerbet-marketing-mix.png?v=1772223991","url":"https:\/\/growthsharematrix.com\/products\/guerbet-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}